Looking for Key Clinical Trial Vendor Management Strategies?
Clinical trials, and in particular oncology studies, can be very complex and often involve multiple parties: Sponsor, CRO (sometimes several…
Busting Myths about the Canadian Regulatory Review Process – An interview with Susanne Picard
In this interview, Susanne Picard, Founder & President of SPharm Inc., answers questions about the Canadian regulatory environment and dispels…
Centralized Ethics Review for Oncology Trials in Canada – An interview with Janet Manzo, Executive Director, Ontario Cancer Research Ethics Board
In this interview Janet Manzo, Executive Director of the Ontario Cancer Research Ethics Board, discusses the development of a province-wide…
Proven Approach to Site Selection is Attracting More Cutting-Edge Oncology Trials to Canada
12 Early-Phase Oncology Programs Started-Up in Canada Over Last 18-Months
Scimega Oncology, (www.scimega.com) the company behind the revolutionary Reverse Feasibility Program, announced it has been awarded
Impact of Clinical Trials on Cancer Patient Outcomes
Those of us who work in clinical operations and oncology drug development can sometimes get caught up in the operations or science and lose sight of the impact our work can have on the lives of people battling cancer. I’d like to share one man’s story to illustrate
Leveraging Canada For Quicker Oncology Site Start-Up
A biotech sponsor in the United States had targeted July 2015 for completion of enrollment for a Phase I dose-finding HER2+BrCa study.
How to Start-Up 9 Oncology Sites in 9 weeks
Over the last decade, increased competition for finite patient populations in the U.S. have led many drug developers to expand…
The Role of Patient Input for Oncology Drug Review – An Interview with CEO of the Canadian Cancer Action Network
In this interview, Marjorie Morrison, CEO of the Canadian Cancer Action Network, talks about the important role patient advocacy groups…
The Secret to Oncology Clinical Trial Performance – An Interview with Denise Deakin
In this interview, conducted by Keystone Marketing's Scott Broady, Denise Deakin, Co-Founder & President of Scimega Oncology answers questions about…
‘Site’ vs. ‘Trial’ CRA assignments and why it matters
During a recent meeting with a sponsor, I was asked whether our clinical research associates (CRAs) were assigned by site,…